Omvoh (mirikizumab-mrkz) is a brand-name drug that’s prescribed for moderate to severe active ulcerative colitis and moderate to severe active Crohn’s disease in adults. It is available as an ...

Ulcerative colitis treatment drug Omvoh, from Eli Lilly, was linked to sustained clinical remission after 4 years, according to new trial data. Image credit: Plexi Images/GHI/UCG/Universal Images ...

INDIANAPOLIS, Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh™ (mirikizumab-mrkz) infusion (300 ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the ...

It is not known whether Omvoh (mirikizumab-mrkz) is safe to receive while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy may determine ...

INDIANAPOLIS, May 5, 2026 /PRNewswire/ -- New long-term data from Eli Lilly and Company (NYSE: LLY) show patients with moderately to severely active ulcerative colitis (UC) treated with Omvoh ...

Weight loss contender Mounjaro may be getting Eli Lilly a lot of public attention these days, but the Indiana pharma giant is busy expanding in immunology, too. With a new FDA approval, Lilly’s ...

Approximately 80% of Omvoh-treated patients in the LUCENT-3 study who achieved clinical remission at one year maintained long-term, corticosteroid-free clinical and endoscopic remission At four years, ...

Landmark VIVID-2 data showed more than 90% of patients who achieved steroid-free remission at one year maintained steroid-free control through three years Additional new data revealed exceptionally ...